Initial survey-based data suggest that population-testing for OC gene mutations for risk stratification may be acceptable to 75% women [35], and 72% women anticipate they would engage in positive health behaviour changes in response to BC/OC risk disclosure following genetic testing [36]. This evidence concerns the gene BGLAP and breast cancer.